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ABSTRACT 
    
Aim: to evaluate  in  HCV-1 subtypes, 1a and 1b, similarities and differences in presenting clinical 
features, and the influence of  baseline  and predictors of response to peg-interferon and ribavirin 
(Peg/RIBA).  
Patients and methods: 1233 naïve patients with HCV genotype-1 infection, 159 (13%) with 
subtype 1a, and 1074 (87%)   with subtype 1b, were treated with Peg-IFN/RIBA at 12 Italian 
centres.  Covariates included in the logistic model were age, gender, BMI,  serum alanine 
aminotransferase (ALT), serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver 
fibrosis, the occurrence of type 2 diabetes, baseline viremia, and  IL28B genotype. 
Results: At multivariate analysis,  baseline characteristics differentiating patients with HCV-1a vs 
HCV-1b were young age, male gender, no F4 fibrosis, and no diabetes.  SVR was achieved by 37% 
of patients with subtype 1b, and  45% of those with subtype  1a, a non significant 8%  difference  
(p=0.069). In patients with subtype 1a, predictors of SVR were IL28B CC (OR=5.78, CI 1.98-
16.83), RVR (OR=4.18, CI 1.66-10.55), female gender (OR=2.83, CI 1.83-6.78), and HCVRNA  
(OR=0.55, CI 0.32-0.96). In patients with subtype 1b  the ranking of predictors was  RVR 
(OR=6.49, CI 4.32-9.73), IL28B  CC (OR=3.32, CI 2.15-4.58), γGT (OR=1.59, CI 0.14-2.22), 
HCVRNA  (OR=0.61, CI 0.47-0.79), and age  (OR=0.01, CI 0.02-0.42).    
Conclusion: in Italy HCV-1 subtype 1a  prevails in young, male patients with less advanced liver 
damage, findings which imply a more recent spreading of the infection with this viral strain. The 
two HCV-1 subtypes appear equally responsive to Peg-IFN/RIBA,  with IL28B genotyping and 
monitoring of RVR mostly influencing the therapeutic response. 
INTRODUCTION  
 
In patients with chronic HCV infection, the efficacy of  pegylated-interferon and Ribavirin (Peg-
IFN and RIBA) is highly  variable, with the HCV genotype exerting a major influence on the 
therapeutic response. Several clinical trials have concordantly reported  that patients infected with 
HCV 1 and 4  strains have only a 40-50% likelihood of achieving a sustained viral response (SVR) 
following  full- dose  Peg-IFN and RIBA for  48 weeks (1-3).  
 
HCV genotype 1 is generally considered as a homogeneous group, but  it  is  composed of at least 
60 subtypes  with differences  in nucleotide and amino acid sequences (4,5). Among subtypes,  1a 
and 1b strains are  prominent.  Major clinical trials  evaluated treatment response among HCV-1a 
and 1b patients grouped together and, consequently, were unable to unveil a differential outcome of   
treatment between the two viral strains. Of available trials (7-14), only  few studies  were 
sufficiently powered to detect an eventual difference,  with  some reporting a lower efficacy of Peg-
IFN and RIBA in HCV-subtype 1a, and other studies  unraveling an  opposite finding. In addition, 
the impact of HCV-1 subtypes on the on-treatment response milestones, such as the rapid viral 
response at treatment week 4 (RVR), has not been extensively investigated.  Finally, no data on the 
distribution of the polymorphism of the IL28B gene and its influence of on-treatment viral response 
between the two HCV subtypes are yet available. 
 
In an observational, real life study carried out in 12 Italian centers, we gathered information   on a 
large group of patients with HCV-1 infection who were treated with Peg-IFN and RIBA (15,16). 
Aims of the present report were to evaluate baseline similarities and differences  between  the  two 
HCV-1 subtypes in relation to patients’ characteristics and  severity of the  hepatic disease, and   to 
assess the   influence of HCV-1 subtypes on  on-treatment response.  Finally, with the intention  to 
reconcile discrepant results reported in different clinical trials on the relevance of subtyping for the 
two HCV-1 strains on SVR, we  pooled our data with those from other  available studies in a meta-
analysis. 
 
 
PATIENTS AND METHODS  
Study design and patients population 
This is a sub-analysis of a multicentre study performed in a  large, homogeneous  cohort of naïve 
patients with  HCV genotype-1. In the present study, we  split the original database of 1233 patients 
according to HCV-1subtypes, 1a or 1b, with the intent to delineate presenting patients’ features and 
their on- and off-treatment therapeutic response. Exclusion and inclusion criteria have been reported 
in previous studies on  this same cohort of patients (14,15).  Patients received  combination therapy 
with Peg-IFN α-2a or α-2b plus RIBA (Rebetol capsules, Schering Corp., Kenilworth, NJ, USA; 
Copegus tablets, Roche, Basel, Switzerland), as recommended by international guidelines: Pegasys 
180 mcg once weekly, subcutaneously; Peg-Intron 1.5 mcg/kg/week, subcutaneously; RIBA 1000 
or 1200 mg/day orally depending on body weight.  Treatment duration lasted 48 weeks for all 
patients who cleared the virus by treatment week 12; therapy was withdrawn at treatment week 24 
for non-responsive patients or for the subset of those with RVR and good predictors at baseline (16-
19). 
 
Measurements  
Serum HCV-RNA was quantified by Cobas Amplicor HCV Monitor Test, v 2.0 (Roche, Basel, 
Switzerland) with a lower detection of 50 IU/L.  Baseline HCV-RNA level was expressed as log10 
IU/ml.  Virologic response was defined as undetectable HCV-RNA at treatment  week 4 (RVR = 
rapid virological response), at week  12 (EVR = early virological response), at end of treatment 
(EOT), and at week  24 off-therapy (SVR). HCV was genotyped by Line Probe Assay (Inno-Lipa 
HCV II; Innogenetics Zwijndrecht, Belgium. We genotyped the IL28B polymorphism  rs12979860  
using the  TaqMan SNP kit (ABI TaqMan) and the ABI 7900HT sequence detection System 
(Applied Biosystems, Foster City, CA, USA).  
 
Meta-analysis 
With the intent to solve discrepancies in reported differences in  treatment outcome between  
patients with HCV subtype 1a or 1b (6-13), we pooled available information in a meta-analysis.  
Trials were identified by searching MEDLINE from 2001  to  2013 by the  following search keys: 
HCV genotypes AND ((therapy)  OR ( Peg-IFN) OR (RIBA)). Studies were excluded if reporting 
data on HIV- or HBV co-infected patients, on treatment experienced patients, treatment schedules 
consisting of conventional interferon as monotherapy or in combination with RIBA, or whenever 
data was not retrievable separately for HCV-1a or 1b. Manual searching included reading through 
reference lists of relevant papers to capture missing studies that met our inclusion criteria. Two 
independent reviewers  (A.A., F.M.) scanned every studies identified by the search to determine 
eligibility. Extracted data included publication date, location of study,  patient inclusion and 
exclusion criteria, mean age, male and female proportion, schedule, dose and duration of therapy. 
Primary outcome measure was rates of SVR  for patients with HCV subtype 1a vs those with 
subtype 1B.   
 
Statistical analysis  
All categorical and continuous variables were described as absolute and percentage frequencies, and 
medians and interquartile ranges (IQR), respectively.  Associations between categorical variables 
with the genotype 1a and 1b infection were evaluated by Pearson Chi-square test or Fisher’s exact 
test. Continuous covariates were compared by Mann-Whitney test. Multivariate analysis was 
performed by stepwise logistic regression model. Covariates included in the model were age, sex, 
BMI,  serum alanine aminotransferase (ALT) levels, serum gamma-glutamiltranspeptidase (γGT) 
levels (abnormal vs normal), platelets counts, liver fibrosis stage (F4 vs <F4), the occurrence of 
type 2 diabetes, baseline viral load (IU/mL), IL28B genotype, type of Peg-IFN alpha (2a vs 2b), 
RVR, EVR, EOT, and SVR. Continuous variables that were not normally distributed were log10 
transformed before analysis. A second model was built considering the same potential explanatory 
variables associated to SVR respectively in HCV subtype 1a and 1b. All analyses were performed 
using the SPS 13 software.  
For the meta-analysis, data were analysed using the Comprehensive Meta-Analysis statistical 
software (version 1.0.25; Biostat, Englewood, NJ, USA).   Pooled Odds Ratios (OR) along with 
corresponding 95%  confidence intervals (CI) were calculated using a random effect model  (20). 
Heterogeneity was investigated by using the I2 statistic with significance set at p < 0.05 (21). 
 
RESULTS  
Baseline characteristics of patients associated with HCV subtype 1a or 1b  
A total of 1233 chronic HCV-1 infected patients were recruited for the study. HCV subtype 1a was 
genotyped in  159 patients (13%),  and  subtype 1b in  the remaining 1074 subjects (87%). The 
disposition of patients’ characteristics  in relation to viral subtypes is reported in Table 1. As to the 
median age, patients with HCV subtype 1a  were 10 years younger (47 vs 57 years, p<0.001), and 
showed  a gender association, being more often males (74% vs 56%; p<0.001). While serum ALT,  
γGT, and viral load  levels did not differ, median platelets counts were higher in HCV subtype 1a, a 
finding  in keeping with a difference in the severity of the hepatic damage: more subtype 1a patients 
had histological or instrumental features of  less advanced (<F4)   fibrosis of the liver (84% vs 70%; 
p<0.001). Despite equal  BMI median values,  more diabetic patients carried  the subtype 1b, at a 
triple frequency of   that encountered in  subtype 1a (12% vs 4%; p<0.003). The distribution of 
IL28B genotypes did not differ  between the two subtypes.  All parameters differentially and 
significantly distributed between the two HCV subtypes at univariate analysis were entered into a 
multivariate logistic model to assess the independent features differentiating the two subtypes. The 
main effects models showed that male gender (O.R. 2,40; C.I. 1,63-3,53), age (O.R. 0,95; C.I. 0,94- 
0,97),  absence of F4 (O.R. 0,59; C.I. 0,37-0,95), and  no type 2 diabetes (O.R. 0,45; C.I. 0,20-1,00) 
were independently associated with subtype 1a.  
 
Virological outcome of  HCV-1a vs HCV-1b following therapy with Peg-IFN and RIBA 
In patients infected with the two HCV subtypes, on-treatment  viral kinetics  are shown in Figure 1.  
At week 4 of treatment, HCV-RNA was undetectable in 28 (28%) patients with subtype 1a,  and in 
244 (23%) patients with subtype 1b (p=0.168). Similarly, EVR and EOT rates were not dissimilar 
between carriers of the HCV-1a or -1b subtype. A total of 470 (38%) patients achieved a SVR, 71 
of 159 (45%) with subtype 1a, and 399 of 1074 (37%)  with subtype 1b, an 8% non significant 
difference  ( p< 0.069). At univariate analysis,  the factors associated with SVR in patients with 
subtypes 1a and 1b were evaluated  separately in two logistic regression models (Supplementary 
Table).  Predictors of SVR for the two HCV subtypes at the multivariate analysis are shown in  
Table 2. Four  factors were independently associated in subtype 1a and, according to their ranking, 
were  IL28B polymorphism CC (OR = 5.78, CI 1.98-16.83), RVR (OR = 4.179, CI 1.66-10.55),   
female gender (OR = 2.83, CI 1.83-6.78), and HCVRNA ( log10 ) (OR = 0.55, CI: 0.32-0.96). In 
patients with subtype 1b the ranking of SVR predictors was RVR (OR=6.49, CI 4.32-9.73), IL28B  
CC (OR=3.32, CI 2.15-4.58),  γGT (OR=1.59, CI 0.14-2.22), HCVRNA  (OR=0.61, CI 0.47-0.79), 
and age  (OR=0.01, CI 0.02-0.42).  
 
 
 
 
 
 
 
Meta-analysis of SVR rates after Peg-IFN and RIBA 
 
Results from the considered studies are summarized in the Supplementary Table. Overall,  4467 
HCV-1 infected  patients were enrolled, 1286 of them (28.9%) with subtype 1a, and the remaining 
3181  patients with subtype 1b. The proportion of subtype 1a patients was >50% in  three studies 
from the USA (6-8), and <30% in most reports from European countries. Of the 8 surveyed trials, 3 
studies ended up with significantly higher SVR rates after treatment with Peg-IFN and RIBA  in 
HCV subtype 1a patients ( 11-13),  and two studies with  significantly better rates in patients with  
subtype 1b (8,9). By pooling results from previous studies with those of the present investigation 
(Figure 2),  the  weighted SVR rates were not different between the two viral strains:  OR = 0.98, CI 
0.72-1.32.  
DISCUSSION  
 
HCV genotype 1 is generally considered as a homogeneous group, but   it shows genetic diversity 
with at least  60   members  identified by  nucleotide sequence variability. HCV subtypes 1a and 1b 
are the major strains, and show   geographical differences, with  subtype 1a being   highly prevalent 
in the USA and subtype 1b in Europe (21,22).  In accordance with the global epidemiology of HCV 
infection, among the studies pooled in the present meta-analysis, the prevalence of   subtype 1a was 
>50% in the three studies from the USA (6-8), and <30% in most reports from European countries. 
In keeping with  previous figures, the majority of  our  Italian patients  (87%)  carried the HCV 
subtype 1b.  Up to now, genotyping for HCV-1 subtypes will not  impact on the day-to-day clinical 
management of chronic HCV infection, whereas conflicting reports  exist on their influence  on the 
outcome following conventional  therapy with Peg-IFN and RIBA (6-13). Recently, several HCV 
inhibitors appear to have selective activity against  HCV 1 subtypes both in vitro and in vivo, with 
subtype 1a appearing  more resistance-prone and less responsive to triple therapy  than subtype 1b 
(25-28). 
 
In the current study, HCV-1 subtypes profiles revealed some variation in the clinical presentation of 
patients infected with  subtype 1a vs those infected with subtype 1b. The most differentiating 
characteristic was a male prevalence and a 10-year younger age of patients with subtype 1a in 
comparison with an equal gender distribution and older age in carriers of the subtype 1b. Of note, 
neither HCV RNA levels nor IL28B distribution  differed in patients infected with the two 
subtypes.  A similar age difference and male prevalence was noted in another Italian study (11). 
These different demographic features may have determined a less severe liver fibrosis in our 
patients with HCV subtype 1a, an observation in keeping with the more recent spreading of the 
infection with this subtype worldwide (22). 
 
As to the sensitivity of HCV-1 subtypes to Peg-IFN and RIBA, there has been no consistency 
among studies  in  regard to a differential responsiveness of subtype 1a vs 1b on either on- and off-
treatment parameters (6-13). In our investigation, HCV clearance by week 4 and 12 of treatments, 
and at the end of treatment did not differ between patients carrying one or the other subtype (Figure 
1). However, a marginal, non-significant 8% difference in SVR rates in subtype 1a vs the other 
subtype was noted in our cohort, a finding which prompted us to pool our results with those 
available from  other 8 trials addressing this topic.  At the meta-analysis of results from the  
previous studies (Figure 2), the two viral strains  were shown to respond equally well to Peg-IFN 
and RIBA, with a pooled  OR of 0.98 (CI 0.72-1.32). This observation would  signify that the 
different outcome between the two subtypes noted following  triple therapy with Peg-IFN and 
RIBA in combination with a direct-acting agent (27,28) needs to be ascribed to the protease 
inhibitor administered, and not to Peg-IFN nor to RIBA.   
The study also pinpoints to some differential predictive features of SVR between the two HCV-1 
subtypes.  In patients with either subtype 1a or 1b, major drivers  of SVR after a full course of Peg-
IFN and RIBA appeared to be the polymorphisms of IL28B and the RVR status, with patients’ age 
and baseline viral load having a marginal influence.  Of note, two other features, i.e, female sex for 
subtype 1a and normal γGT levels for subtype 1b, were also shown to bear a moderate impact on  a 
successful outcome of therapy. Fibrosis stage and prediction of  viral response to treatment have 
been linked to γGT activity (30,), an indirect  marker of oxidative stress in relation to glutathione 
metabolism (29). Advanced fibrosis of the liver did not correlate with  SVR in our cohort, a 
correlation which obscured and/or incorporated by the impact of γGT on SVR. Finally, the 
relevance of female gender on SVR rates in patients with subtype 1a but not in those with the other 
subtype awaits further confirmation in a larger cohort of carriers of the former viral strain. 
In conclusion,  our study reveals some differential features in the presentation of patients with 
HCV-1 infection, with  subtype 1a carriers being  more frequently younger,  of male gender, and 
with a less advanced stage of liver fibrosis.   As to the claimed better efficacy of treatment with 
Peg-IFN and RIBA for HCV-1a patients, either the results of the present investigation as well as the 
pooled data from 8 other clinical trials on this topic document an equal responsiveness of the two  
HCV subtypes to this therapeutic regimen. IL28B genotype and attainment of the RVR status 
appear the major driver of a favorable outcome following Peg-IFN and RIBA therapy in both HCV-
1 subtypes.  
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Legend to Figures 
Figure 1: Viral responses at week 4 (RVR), week 12 (EVR), end-of-treatment (EOT), and at week 
24 off-treatment (SVR) in HCV-1 patients with subtype 1a or 1b. 
Figure 2: Forrest plot of the studies that compared sustained viral response (SVR) rates in  HCV-1 
patients with subtype 1a or 1b. 
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